Stock Scorecard
Stock Summary for Takeda Pharmaceutical Company (TAK) - $13.07 as of 4/26/2024 3:49:58 PM EST
Total Score
14 out of 29
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for TAK
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for TAK
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for TAK
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for TAK
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for TAK
Financial Details for TAK
Company Overview |
|
|---|---|
| Ticker | TAK |
| Company Name | Takeda Pharmaceutical Company |
| Country | USA |
| Description | Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 5/9/2024 |
Stock Price History |
|
| Last Day Price | 13.07 |
| Last Day Price Updated | 4/26/2024 3:49:58 PM EST |
| Last Day Volume | 0 |
| Average Daily Volume | 1,746,041 |
| 52-Week High | 16.42 |
| 52-Week Low | 12.91 |
| Last Price to 52 Week Low | 1.24% |
Valuation Measures |
|
| Trailing PE | 36.19 |
| Industry PE | 79.17 |
| Sector PE | 56.64 |
| 5-Year Average PE | 9.29 |
| Free Cash Flow Ratio | 0.14 |
| Industry Free Cash Flow Ratio | 12.71 |
| Sector Free Cash Flow Ratio | 30.65 |
| Current Ratio Most Recent Quarter | 1.06 |
| Total Cash Per Share | 91.90 |
| Book Value Per Share Most Recent Quarter | 4,297.22 |
| Price to Book Ratio | 0.95 |
| Industry Price to Book Ratio | 5.66 |
| Sector Price to Book Ratio | 22.15 |
| Price to Sales Ratio Twelve Trailing Months | 0.01 |
| Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.17 |
Share Statistics |
|
| Total Shares Outstanding | 3,137,830,000 |
| Market Capitalization | 41,011,438,100 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | 9/28/2023 |
| Last Dividend Amount | 0.31 |
| Current Dividend Amount | 0.32 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 0.32 |
| Trailing Annual Dividend Yield | 2.45% |
| Forward Annual Dividend Rate | 0.30 |
| Forward Annual Dividend Yield | 2.29% |
| 5-Year Dividend Payments Count | 9 |
| 3-Year Average Dividend Yield | 4.84% |
| 5-Year Average Dividend Yield | 4.68% |
| 1-Year Dividend Growth Rate Percentage | -4.64% |
| 3-Year Dividend Growth Rate Percentage | -11.52% |
| 5-Year Dividend Growth Rate Percentage | -6.65% |
| All-Time Dividend Growth Rate Percentage | 1.99% |
| Dividend Payout Ratio | 88.63% |
Income Statement |
|
| Quarterly Earnings Growth YOY | -12.10% |
| Annual Earnings Growth | 37.80% |
| Reported EPS 12 Trailing Months | 0.36 |
| Reported EPS Past Year | 18.49 |
| Reported EPS Prior Year | 0.76 |
| Net Income Twelve Trailing Months | 178,219,000,000 |
| Net Income Past Year | 317,017,000,000 |
| Net Income Prior Year | 230,059,000,000 |
| Quarterly Revenue Growth YOY | 1.30% |
| 5-Year Revenue Growth | 17.87% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 288,359,000,000 |
| Total Cash Past Year | 533,530,000,000 |
| Total Cash Prior Year | 849,695,000,000 |
| Net Cash Position Most Recent Quarter | -4,005,513,000,000 |
| Net Cash Position Past Year | -3,509,211,000,000 |
| Long Term Debt Past Year | 4,042,741,000,000 |
| Long Term Debt Prior Year | 4,141,418,000,000 |
| Total Debt Most Recent Quarter | 4,293,872,000,000 |
| Equity to Debt Ratio Past Year | 0.61 |
| Equity to Debt Ratio Most Recent Quarter | 0.61 |
| Total Stockholder Equity Past Year | 6,354,122,000,000 |
| Total Stockholder Equity Prior Year | 5,683,019,000,000 |
| Total Stockholder Equity Most Recent Quarter | 6,741,934,000,000 |
Options |
|
| Put/Call Ratio | 1.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.26 |
| MACD Signal | -0.27 |
| 20-Day Bollinger Lower Band | 13.13 |
| 20-Day Bollinger Middle Band | 14.21 |
| 20-Day Bollinger Upper Band | 15.30 |
| Beta | 0.54 |
| RSI | 30.61 |
| 50-Day SMA | 14.69 |
| 200-Day SMA | 14.69 |
System |
|
| Modified | 4/27/2024 12:33:08 PM EST |